155 related articles for article (PubMed ID: 24474573)
1. An association of myeloproliferative neoplasms and obliterative portal venopathy.
Mayer JE; Schiano TD; Fiel MI; Hoffman R; Mascarenhas JO
Dig Dis Sci; 2014 Jul; 59(7):1638-41. PubMed ID: 24474573
[No Abstract] [Full Text] [Related]
2. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
3. Leukemia and related disorders.
Anderson RE
Hum Pathol; 1971 Dec; 2(4):505-14. PubMed ID: 5286449
[No Abstract] [Full Text] [Related]
4. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
5. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
6. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly.
Nayak NC; Ramalingaswami V
Arch Pathol; 1969 Apr; 87(4):359-69. PubMed ID: 5766763
[No Abstract] [Full Text] [Related]
7. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy.
Abraham SC; Kamath PS; Eghtesad B; Demetris AJ; Krasinskas AM
Am J Surg Pathol; 2006 Nov; 30(11):1454-61. PubMed ID: 17063088
[TBL] [Abstract][Full Text] [Related]
8. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hasselbalch HC
Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
[TBL] [Abstract][Full Text] [Related]
9. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
Hasselbalch HC; Bjørn ME
Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
[TBL] [Abstract][Full Text] [Related]
10. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
Greenberg PL
Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
[No Abstract] [Full Text] [Related]
11. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
12. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.
Gianelli U; Vener C; Raviele PR; Moro A; Savi F; Annaloro C; Somalvico F; Radaelli F; Franco V; Deliliers GL
Leuk Lymphoma; 2006 Sep; 47(9):1774-81. PubMed ID: 17064987
[TBL] [Abstract][Full Text] [Related]
13. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
14. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy.
Wanless IR; Peterson P; Das A; Boitnott JK; Moore GW; Bernier V
Hepatology; 1990 Nov; 12(5):1166-74. PubMed ID: 2227815
[TBL] [Abstract][Full Text] [Related]
15. Obliterative portal venopathy: a study of 48 children.
Franchi-Abella S; Fabre M; Mselati E; De Marsillac ME; Bayari M; Pariente D; Jacquemin E; Bernard O
J Pediatr; 2014 Jul; 165(1):190-193.e2. PubMed ID: 24768253
[TBL] [Abstract][Full Text] [Related]
16. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
17. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
18. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
Reilly JT
Leukemia; 2008 Oct; 22(10):1818-27. PubMed ID: 18754027
[TBL] [Abstract][Full Text] [Related]
20. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
[No Abstract] [Full Text] [Related]
[Next] [New Search]